These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36945329)

  • 1. Efficacy of a rehabilitation program using minor muscles in colorectal cancer patients with chemotherapy-induced neuropathy: preliminary study.
    Hong KS; Chung SS; Kim KH; Lee RA
    Korean J Clin Oncol; 2022 Jun; 18(1):11-16. PubMed ID: 36945329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study.
    Hsu HT; Wu LM; Lin PC; Juan CH; Huang YY; Chou PL; Chen JL
    Medicine (Baltimore); 2020 Feb; 99(6):e19029. PubMed ID: 32028414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
    Ohtani H; Arimoto Y; Nishio K; Kanamiya Y; Oba H; Adachi K; Shintani M; Nakamura R; Yui S
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1769-74. PubMed ID: 18931586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Patient-Reported Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Survivors.
    Teng C; ; Blinman PL; Vardy JL
    J Natl Compr Canc Netw; 2022 Dec; 20(12):1308-1315. PubMed ID: 36509075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
    J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
    Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
    J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin-induced neuropathy and colo-rectal cancer patient's quality of life: Practical lessons from a prospective cross-sectional, real-world study.
    Prutianu I; Alexa-Stratulat T; Cristea EO; Nicolau A; Moisuc DC; Covrig AA; Ivanov K; Croitoru AE; Miron MI; Dinu MI; Ivanov AV; Marinca MV; Radu I; Gafton B
    World J Clin Cases; 2022 Apr; 10(10):3101-3112. PubMed ID: 35647128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.
    Kim GP; Sargent DJ; Mahoney MR; Rowland KM; Philip PA; Mitchell E; Mathews AP; Fitch TR; Goldberg RM; Alberts SR; Pitot HC
    J Clin Oncol; 2009 Jun; 27(17):2848-54. PubMed ID: 19380443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer: a Korean single-center experience.
    Kim JH; Park SJ; Park MI; Moon W; Kim SE; Ku KH; Song SE; Kim JH
    Korean J Gastroenterol; 2014 Jan; 63(1):18-24. PubMed ID: 24463284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
    Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
    Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
    Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
    Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.
    Kleckner IR; Kamen C; Gewandter JS; Mohile NA; Heckler CE; Culakova E; Fung C; Janelsins MC; Asare M; Lin PJ; Reddy PS; Giguere J; Berenberg J; Kesler SR; Mustian KM
    Support Care Cancer; 2018 Apr; 26(4):1019-1028. PubMed ID: 29243164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer.
    Simpson D; Dunn C; Curran M; Goa KL
    Drugs; 2003; 63(19):2127-56. PubMed ID: 12962525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolving role of oxaliplatin in the management of colorectal cancer.
    de Gramont A; Schmoll HJ; Cervantes A; Tournigand C
    Colorectal Dis; 2003 Nov; 5 Suppl 3():10-9. PubMed ID: 23573556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
    Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
    Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.
    Sugimoto M; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Okubo Y; Nakamura J; Takasumi M; Hashimoto M; Kato T; Kobashi R; Hikichi T; Ohira H
    BMC Cancer; 2021 Dec; 21(1):1319. PubMed ID: 34886831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel.
    Ventzel L; Jensen AB; Jensen AR; Jensen TS; Finnerup NB
    Pain; 2016 Mar; 157(3):560-568. PubMed ID: 26529271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer.
    Jonker D; Rumble RB; Maroun J;
    Curr Oncol; 2006 Oct; 13(5):173-84. PubMed ID: 22792014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
    Rothenberg ML; Oza AM; Bigelow RH; Berlin JD; Marshall JL; Ramanathan RK; Hart LL; Gupta S; Garay CA; Burger BG; Le Bail N; Haller DG
    J Clin Oncol; 2003 Jun; 21(11):2059-69. PubMed ID: 12775730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.